IBIO vs. SHPH, RNAZ, PCSA, TENX, PULM, ASLN, CANF, AIMD, KTTA, and UPC
Should you be buying iBio stock or one of its competitors? The main competitors of iBio include Shuttle Pharmaceuticals (SHPH), TransCode Therapeutics (RNAZ), Processa Pharmaceuticals (PCSA), Tenax Therapeutics (TENX), Pulmatrix (PULM), ASLAN Pharmaceuticals (ASLN), Can-Fite BioPharma (CANF), Ainos (AIMD), Pasithea Therapeutics (KTTA), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical preparations" industry.
iBio (NYSE:IBIO) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.
7.9% of iBio shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 1.1% of iBio shares are held by insiders. Comparatively, 40.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Shuttle Pharmaceuticals had 1 more articles in the media than iBio. MarketBeat recorded 5 mentions for Shuttle Pharmaceuticals and 4 mentions for iBio. Shuttle Pharmaceuticals' average media sentiment score of 0.65 beat iBio's score of 0.51 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media.
iBio has a beta of -3.22, meaning that its share price is 422% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -1.18, meaning that its share price is 218% less volatile than the S&P 500.
iBio and Shuttle Pharmaceuticals both received 0 outperform votes by MarketBeat users.
Shuttle Pharmaceuticals has lower revenue, but higher earnings than iBio.
Shuttle Pharmaceuticals' return on equity of -132.80% beat iBio's return on equity.
Summary
Shuttle Pharmaceuticals beats iBio on 6 of the 9 factors compared between the two stocks.
Get iBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
